EIF4E and neoplasm: A 4E-antisense oligonucleotide to reduce the expression of eIF4E was shown to inhibit tumor growth in a prostate cancer xenograft model [89] and was safe in humans in a Phase I clinical trial, though it did not demonstrate anti-tumor activity as a single agent [90].